ReviewFrontiers in pharmacology2025
Pharmacological effects, formulations, and clinical research progress of curcumin.
Review in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Effects of Zingiberaceae-derived interventions on memory-related and other cognitive outcomes in adults: a systematic review and meta-analysis.Frontiers in nutrition · 2026Pooled it
- Enhanced Oral Delivery of Turmeric Extract via Spray-Dried Microparticles: Biopharmaceutical Performance and In Vitro Microbiota Modulation.International journal of molecular sciences · 2026Article
- Curcumin ameliorates hepatic insulin resistance by activating PINK1/Parkin-mediated mitophagy.Scientific reports · 2026Article
- Unveiling the effect of curcumin on ion channels of SBMA motoneuron-derived cells and human IPSC-derived neurons: initial electrophysiological findings.European biophysics journal : EBJ · 2026Article
- Curcumin Between Pleiotropic Potential and Translational Constraints.International journal of molecular sciences · 2026Review
- Smart nanoparticle delivery systems for curcumin: a targeted strategy to enhance anticancer efficacy and bioavailability.Journal of materials science. Materials in medicine · 2026Review
- Curcumin treatment attenuates methotrexate-induced nephrotoxicity in rats by inhibiting inflammation and fibrosis.Journal of molecular histology · 2026Article
- Curcumin as theranostics: imaging-guided therapeutics in oncology and neurodegenerative diseases.Frontiers in nutrition · 2026Review
- Neuroprotective effects of curcumin, memantine, and caffeic acid in a Rat model of cerebral ischemia-reperfusion injury.Frontiers in pharmacology · 2026Article
- Antioxidant biomaterials in intervertebral disc regeneration: current status and future clinical translation.Frontiers in bioengineering and biotechnology · 2026Review
- Redox Homeostasis in Poultry/Animal Production.Antioxidants (Basel, Switzerland) · 2025Article
- Nanostructured Delivery Systems for Curcumin: Improving Bioavailability and Plaque-Targeting Efficacy in Atherosclerosis.Pharmaceutics · 2025Review
- Nanocarrier-Based Delivery Systems for Natural Compounds Across Research Stages.Materials (Basel, Switzerland) · 2025Review
- Curcumin in oral health: mechanisms, clinical evidence, and delivery strategies.Frontiers in pharmacology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Curcumin, a polyphenolic compound derived from the traditional Chinese medicine turmeric, which has a variety of pharmacological effects, including anti-cancer, anti-inflammatory, antioxidant, and antiviral properties. However, its clinical application is hindered by low solubility and bioavailability. To overcome these limitations, researchers have developed various formulations such as nanoformulations, solid dispersions, and microspheres. These advancements have led to improved therapeutic effects and have facilitated the progression of clinical research, primarily focusing on Phase I and Phase II trials for conditions like diabetes, obesity, and metabolic syndrome. In recent years, there has been a noticeable increase in Phase III and IV clinical trials, particularly concerning oral and dental diseases and arthritis. This article reviews recent literature from both domestic and international sources, providing a comprehensive overview of curcumin's research progress, including its pharmacological mechanisms, formulation developments, and clinical studies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.